X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Biocon Ltd with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs ACTAVIS (US) - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 BIOCON LTD   ACTAVIS
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
ACTAVIS
Dec-14
BIOCON LTD/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,18819,396-   
Low Rs30511,831-   
Sales per share (Unadj.) Rs68.73,492.7-  
Earnings per share (Unadj.) Rs7.6-435.9-  
Cash flow per share (Unadj.) Rs14.0320.4-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.10-  
Book value per share (Unadj.) Rs86.37,575.5-  
Shares outstanding (eoy) m600.00265.90-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.94.5 243.0%   
Avg P/E ratio x98.9-35.8 -275.9%  
P/CF ratio (eoy) x53.448.7 109.7%  
Price / Book Value ratio x8.62.1 419.5%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m447,9004,151,646 10.8%   
No. of employees `0006.121.6 28.5%   
Total wages/salary Rs m9,3110-   
Avg. sales/employee Rs Th6,705.842,995.8 15.6%   
Avg. wages/employee Rs Th1,514.20-   
Avg. net profit/employee Rs Th736.9-5,365.4 -13.7%   
INCOME DATA
Net Sales Rs m41,234928,708 4.4%  
Other income Rs m2,062-2,318 -89.0%   
Total revenues Rs m43,296926,390 4.7%   
Gross profit Rs m8,291119,306 6.9%  
Depreciation Rs m3,851201,099 1.9%   
Interest Rs m61529,293 2.1%   
Profit before tax Rs m5,887-113,405 -5.2%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-8,319 0.0%   
Tax Rs m1,569-5,830 -26.9%   
Profit after tax Rs m4,531-115,893 -3.9%  
Gross profit margin %20.112.8 156.5%  
Effective tax rate %26.75.1 518.4%   
Net profit margin %11.0-12.5 -88.1%  
BALANCE SHEET DATA
Current assets Rs m41,486489,310 8.5%   
Current liabilities Rs m21,413356,851 6.0%   
Net working cap to sales %48.714.3 341.3%  
Current ratio x1.91.4 141.3%  
Inventory Days Days6458 110.2%  
Debtors Days Days9466 142.1%  
Net fixed assets Rs m50,661113,405 44.7%   
Share capital Rs m3,0000-   
"Free" reserves Rs m48,8080-   
Net worth Rs m51,8082,014,334 2.6%   
Long term debt Rs m17,8981,055,551 1.7%   
Total assets Rs m99,8973,691,612 2.7%  
Interest coverage x10.6-2.9 -368.2%   
Debt to equity ratio x0.30.5 65.9%  
Sales to assets ratio x0.40.3 164.1%   
Return on assets %5.2-2.3 -219.6%  
Return on equity %8.7-5.8 -152.0%  
Return on capital %9.6-3.0 -320.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m4,7100-   
CASH FLOW
From Operations Rs m6,621159,477 4.2%  
From Investments Rs m-6,840-381,850 1.8%  
From Financial Activity Rs m-2,397214,544 -1.1%  
Net Cashflow Rs m-2,612-7,828 33.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare BIOCON LTD With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare BIOCON LTD With: MERCK LTD  ALEMBIC PHARMA  VENUS REMEDIES  DISHMAN PHARMA  IPCA LABS  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 22, 2019 (Close)

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS